Manipulating melatonin in managing mood

Acta Psychiatrica Scandinavica

Volumn 128, Issue S444, 2013, Pages 16-23

  Boyce, P ^a,b   Hopwood, M ^c  

^a University of Sydney   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Affective disorder; Bright light; Circadian rhythm; Melatonin; Sleep deprivation

Indexed keywords

AGOMELATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SERTRALINE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BLUE LIGHT; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; DEPRESSION; FOLLOW UP; GENETIC REGULATION; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; PHOTOPERIODICITY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA GANGLION CELL; SEASONAL AFFECTIVE DISORDER; SLEEP DEPRIVATION; SLEEP PATTERN; SUPERIOR CERVICAL GANGLION; SUPRACHIASMATIC NUCLEUS; METABOLISM; MOOD DISORDERS; PHYSIOLOGY; PROCEDURES;

CIRCADIAN RHYTHM; HUMANS; MELATONIN; MOOD DISORDERS; PHOTOTHERAPY; SLEEP DEPRIVATION;

EID: 84881231265     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12175     Document Type: Article

References (69)

1. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
3. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2009;43:594-605.
4. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
5. Malhi GS, Adams D, Porter R, et al. Clinical practice recommendations for depression. Acta Psychiatr Scand 2009;119(Suppl 439):8-26.
6. Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 2002;17(Suppl 1):S1-S12.
7. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.
9. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008;23:571-585.
10. Kronfeld-Schor N, Einat H. Circadian rhythms and depression: human psychopathology and animal models. Neuropharmacology 2012;62:101-114.
11. Lewy AJ. Circadian misalignment in mood disturbances. Curr Psychiatry Rep. 2009;11:459-465.
12. Lader M. Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacol 2007;17:743-755.
13. Kennaway DJ, van Dorp CF. Free-running rhythms of melatonin, cortisol, electrolytes, and sleep in humans in Antarctica. Am J Physiol 1991;260:R1137-R1144.
14. Bass J. Circadian topology of metabolism. Nature 2012;491:348-356.
15. Arendt J. Melatonin and human rhythms. Chronobiol Int 2006;23:21-37.
16. Pevet P. Melatonin: from seasonal to circadian signal. J Neuroendocrinol 2003;15:422-426.
17. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004;5:523-532.
18. Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogues Clin Neurosci 2008;10:337-343.
19. Avery DH, Wildschiødtz G, Rafaelsen OJ. Nocturnal temperature in affective disorder. J Affect Disord 1982;4:61-71.
20. Koenigsberg HW, Teicher MH, Mitropoulou V, et al. 24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. J Psychiatr Res 2004;38:503-511.
21. Souetre E, Salvati E, Belugou J-L, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989;28:263-278.
22. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol 2008;18:701-711.
23. Arendt J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003;15:427-431.
24. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev 2002;6:407-420.
25. Revell VL, Molina TA, Eastman CI. Human phase response curve to intermittent blue light using a commercially available device. J Physiol 2012;590:4859-4868.
26. Albrecht U. Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 2012;74:246-260.
27. Lewy AJ, Sack RL, Miller LS, Hoban TM. Antidepressant and circadian phase-shifting effects of light. Science 1987;235:352-354.
28. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 2002;295:1065-1070.
29. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science 1980;210:1267-1269.
30. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002;295:1070-1073.
31. Ebadi M, Govitrapong P. Neural pathways and neurotransmitters affecting melatonin synthesis. J Neural Transm Suppl 1986;21:125-155.
32. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-110.
33. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998;12:1211-1220.
34. Pandi-Perumal SR, Smits M, Spence W, et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1-11.
35. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-392.
36. Khalsa SB, Jewett ME, Cajochen C, Czeisler CA. A phase response curve to single bright light pulses in human subjects. J Physiol 2003;549:945-952.
37. Revell VL, Burgess HJ, Gazda CJ, Smith MR, Fogg LF, Eastman CI. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab 2006;91:54-59.
38. Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for affective disorders: a clinicians manual for light and wake therapy. Basel: Karger, 2009.
39. Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163:805-812.
40. Even C, Schroder CM, Friedman S, Rouillon F. Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Disord 2008;108:11-23.
41. Khalsa SBS, Jewett ME, Duffy JF, Czeisler CA. The timing of the human circadian clock is accurately represented by the core body temperature rhythm following phase shifts to a three-cycle light stimulus near the critical zone. J Biol Rhythms 2000;15:524-530.
42. Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr 2005;10:647-663; quiz 72.
43. Wirz-Justice A, Benedetti F, Berger M, et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 2005;35:939-944.
44. Norman T. Melatonin: hormone of the night. Acta Neuropsychiatr 2009;21:263-265.
45. Wirz-Justice A. Biological rhythms and depression: treatment opportunities. WPA Bulletin on Depression 2008;12:5-8.
46. Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am J Psychiatry 1976;133:1181-1186.
47. Serfaty MA, Osborne D, Buszewicz MJ, Blizard R, Raven PW. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010;25:132-142.
48. Giedke H, Schwärzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev 2002;6:361-377.
49. Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Kasper S. Therapeutic sleep deprivation and phototherapy. Wien Med Wochenschr 1999;149:520-524.
50. Benedetti F, Barbini B, Colombo C, Smeraldi E. Chronotherapeutics in a psychiatric ward. Sleep Med Rev 2007;11:509-522.
51. Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother 2011;11:961-970.
52. Martiny K, Refsgaard E, Lund V, et al. A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J Clin Psychiatry 2012;73:1234.
53. Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy. Depress Anxiety 2002;16:1-3.
54. Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatry 1996;39:16-21.
55. Guducu F, Caliyurt O, Vardar E, Tuglu C, Abay E. Combination therapy using sertraline with sleep deprivation and light therapy compared to sertraline monotherapy for major depressive disorder. Turk Psikiyatri Derg 2005;16:245.
56. Gottlieb J, Terman M. Outpatient triple chronotherapy for bipolar depression: case report. J Psychiatric Pract 2012;18:373.
57. Wu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009;66:298-301.
58. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547.
59. Gorgulu Y, Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull 2009;80:158.
60. Voderholzer U, Fiebich BL, Dersch R, et al. Effects of sleep deprivation on nocturnal cytokine concentrations in depressed patients and healthy control subjects. J Neuropsychiatry Clin Neurosci 2012;24:354-366.
61. Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010;11:148-153.
62. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-333.
63. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-1732.
64. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010;25:305.
65. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109.
66. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-247.
67. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:1128.
68. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24:479-499.
69. Montejo A, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010;24:111-120.